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SUMMARY
Background: Few studies conducted outside of Asia have shown that lower uri-
nary tract symptoms (LUTS) could be a concern for cancer patients. This gap
necessitates more research on LUTS among cancer patients in Asia, particularly
regarding associated factors and the relationship between quality of life and LUTS.
Objectives: This study investigates the prevalence, associated factors, and rela-
tionship to quality of life of LUTS based on a sample of cancer patients. Design:
A cross-sectional, questionnaire survey. Settings/participants: This study was
conducted at two oncology outpatient departments in two hospitals in Taiwan,
and included 134 Asian cancer patients. Methods: We collected information
about each participant’s individual characteristics, personal habits, LUTS, and qual-
ity of life by using a questionnaire. We calculated descriptive statistics to demon-
strate the distribution of collected information, and used multivariate logistic
regression to identify the factors associated with LUTS. We used Student’s t-test
to compare the mean quality of life scores for participants with and without LUTS.
Results: Ninety-nine (73.9%) participants experienced at least one type of LUTS,
and the prevalence rates for various types of LUTS ranged from 3.7% to 52.2%.
Radiotherapy and the time since the diagnosis of cancer were associated with
LUTS. Participants with LUTS reported lower quality of life scores than participants
without LUTS. Conclusions: The high prevalence of LUTS suggests that cancer
treatment might be linked to LUTS, which in turn has a negative effect on a
patient’s quality of life. These results suggest that future research should involve
studies in larger, more homogeneous samples. Health care providers should moni-
tor the presence of LUTS and deliver the management and treatments of LUTS to
optimise cancer patients’ quality of life.
What’s known
Few studies conducted outside of Asia have shown
that lower urinary tract symptoms (LUTS) could be
a concern for cancer patients, and few of these
studies have investigated LUTS among Asian cancer
patients. Previous research on LUTS among cancer
patients is limited, particularly regarding the
associated factors and relationship to the quality of
life.
What’s new
The prevalence of LUTS among cancer patients is
high. Radiotherapy and the time since the diagnosis
of cancer might be linked to LUTS. Cancer patients
with LUTS reported lower quality of life scores than
those without symptoms. These results contribute
to knowledge about LUTS among Asian cancer
patients.
Background
Cancer patients frequently experience multiple symp-
toms concurrently. Most cancer patients experience
more (3–18) concurrent symptoms than patients
with other chronic diseases (1). These symptoms are
major problems for cancer patients, health care pro-
viders, and family caregivers. Unrelieved symptoms
have negative effects on patients’ health conditions
and health-related quality of life (HRQL) (2).
Forty-five percent of cancer survivors (n = 321)
reported that urinary incontinence (UI) might be
attributed to cancer (3). Alfano et al. (4) found that
46–58% of breast cancer patients (n = 803) experi-
enced difficulty with bladder control. Gift et al. (5)
reported that 15% of lung cancer patients (n = 220)
experienced urinary problems, and 68% indicated
getting up at night to urinate. These findings suggest
that lower urinary tract symptoms (LUTS) could be
a concern for cancer patients (3–5). However, few
studies on LUTS among cancer patients involve non-
Asian populations, and information on LUTS among
Asian cancer patients is lacking.
Storage, voiding, and post-micturition are the
three main symptom groups of LUTS. Storage symp-
toms, which occur during the filling and storage
phase of the bladder, include increased daytime uri-
nary frequency, nocturia, urinary urgency, and UI.
Voiding symptoms, such as slow stream, splitting or
spraying, intermittent stream, hesitancy, straining,
and terminal dribble, occur during the voiding
phase. Post-micturition symptoms, including a feel-
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ing of incomplete emptying and post-micturition
dribble, occur immediately after micturition (6). The
prevalence of LUTS ranges from 48% to 64% among
the general population (7–9). The high prevalence of
LUTS among the general population warrants special
attention to these relatively neglected symptoms
among cancer patients.
People without LUTS have better HRQL and
physical/mental health than people with LUTS
(10,11), and symptom severity is negatively associ-
ated with HRQL and sleep (12,13). Although LUTS
have widespread human and psychosocial implica-
tions that negatively affect HRQL (10,11), only one-
fourth to one-third of people with LUTS seek profes-
sional help (14,15). Previous studies have shown that
sleep disturbances are common in cancer patients
(5,16,17). Cancer patients who received treatment
(e.g. chemotherapy, radiotherapy, and surgery) in the
previous 6 months have more sleep disturbances
than those who did not (16). Other research has
shown an association between LUTS and sleep dis-
turbances (13), and further research is needed to
examine this association in cancer patients.
Research on LUTS among cancer patients is lim-
ited, particularly regarding associated factors and the
relationship between HRQL and LUTS. Therefore,
this study investigates the prevalence, associated fac-
tors, and relationship to HRQL of LUTS among can-
cer patients. The results of this study contribute to
knowledge about LUTS among Asian cancer patients.
This study is important to cancer patients because it
increases the awareness of this common health con-
cern, and opens channels of communication among
cancer patients with LUTS and among oncology
health care providers.
Methods
Study design and ethical approval
This study is a cross-sectional, questionnaire survey.
We conducted a pilot study before the main study.
The pilot study was conducted to obtain feedback
from cancer patients on possible problem areas (e.g.
difficulty of interpreting terms or statements) in the
questionnaire. The pilot study also confirmed the
adequacy of the data collection process. Ethical
approval was obtained from two selected hospitals
before the study commenced.
Setting and sample
This study was conducted at two oncology outpatient
departments in two hospitals in Taiwan. The outpa-
tient departments participating in this study assigned
a number to each qualified patient, and generated
two sampling lists and a systematic sampling method
to select every third patient listed. If the selected
patient refused to participate, no patient was
recruited as a substitute. Inclusion criteria included a
confirmed diagnosis of certain cancers for 6 months
to 5 years, age equal or more than 18 years, cogni-
tive clarity, ability to communicate, and awareness of
cancer diagnosis. We excluded patients with prostate
cancer because information on LUTS is already avail-
able for this population. Other exclusion criteria
included (1) major cognitive impairment or inability
to provide informed consent, and (2) severe physical
weakness to tolerate an interview of 20–30 min.
The main study consisted of interviews with 140
cancer patients. We excluded questionnaires com-
pleted by cancer patients who currently experienced
burning during urination (n = 6) from analysis
because they might have experienced a urinary tract
infection (UTI) at the time of data collection. We
used the information collected from 134 cancer
patients for data analysis.
Measures
The questionnaire in this study included four sec-
tions covering various areas: (1) individual character-
istics, (2) personal habits, (3) LUTS, and (4) HRQL.
The majority of items in two sections (individual
characteristics and personal habits) were derived
from the Taiwan Teacher Bladder Survey (TTBS)
(18). The LUTS items in the study questionnaire
were the same as the LUTS items in the TTBS. We
used the Short-Form 36 Health Survey (SF-36), Tai-
wan version, to measure HRQL.
The internal consistency of the LUTS construct,
content validity, and the test-retest reliability of the
TTBS were adequate (18). For generating the study
questionnaire, we modified the items in the TTBS to
reduce the interview duration. First, we eliminated
some items related to teachers’ working experience/
employment setting, and some conditions (e.g. preg-
nancy) that would be uncommon among cancer
patients. Second, we added items about patient sex
and disease (primary cancer site, cancer stage, time
since the diagnosis of cancer, treatments received,
and treatment status). Third, any items related to
frequency and duration of LUTS became the sub-
items of the item indicating the presence of LUTS.
Patients who did not experience certain types of
LUTS could skip the related sub-items. For example,
participants who did not experience UI could skip
the sub-items related to the frequency and duration
of UI. Fourth, we added one item related to sleep
because sleep disturbances might be linked to LUTS
(13). The final questionnaire included 40 items: indi-
vidual characteristics (18 items), personal habits (8
items), LUTS including UTI (10 items), LUTS-
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related disturbances (two items), and help-seeking
behaviour (two items).
Six experts (two oncologists, one oncology nurse,
and three cancer patients) were invited to review the
content validity of the study questionnaire. These
experts graded each item based on the precision of
the statement/response options and the appropriate-
ness to the research aims of this study. We con-
firmed the grade system and criterion for ensuring
content validity based on the standard proposed by
Lynn (19). The 6 experts confirmed the content
validity of the study questionnaire. Thirty partici-
pants in the pilot study did not report any specific
problems with the study questionnaire or the data
collection process. This pilot study confirmed the
adequacy of the data collection process and helped
streamline the study procedure.
We collected information on the participants’ sex,
age, body height/weight, disease and health-related
conditions (e.g. history of diabetes mellitus). For per-
sonal habits, we collected information on individual
smoking habits, bladder habits, and habits of fluid
and caffeine consumption. The classification methods
used for categorising each participant’s individual
characteristics and personal habits were the same as
those used in a previous study (20). We categorised
participants’ bladder habits and fluid consumption
habits into two levels (good or poor) based on their
responses to items related to delaying urination,
restricting hydration, and the likelihood of adequate
hydration. Each participant’s cancer stage was con-
firmed by his or her primary oncologist(s) using the
labels of Stage I, II, III, or IV to represent the cancer
stage. Each stage was based on the TNM staging sys-
tem developed and maintained by the American Joint
Committee on Cancer (21). Treatments received
included chemotherapy or target therapy, surgery,
radiotherapy, and endocrine therapy. Treatment status
included 3 categories: active treatment (e.g. chemo-
therapy/target therapy, surgery, radiotherapy, or endo-
crine therapy), post-treatment for less than 6 months,
and post-treatment for more than 6 months.
This study defines the presence of 8 different
LUTS as follows: self-reported occurrence of UI,
increased daytime urinary frequency, urinary
urgency, nocturia, intermittent stream, weak urinary
stream, hesitancy, and a feeling of incomplete empty-
ing during the past 6 months. These LUTS were cho-
sen because they facilitate the comparisons between
the findings reported in the literature (7–9) and the
results reported in the current study. We collected
information about UTI to exclude patients who
might experience UTI at the time of data collection
because several LUTS (e.g. UI, urinary frequency,
and urinary urgency) are associated with UTI. Most
definitions of individual LUTS used in this study are
based on a standardisation report proposed by the
International Continence Society (6,22). A related
study has reported all of these definitions of individ-
ual LUTS (23). This study defines the presence of
LUTS as the LUTS occurring at least one or several
times a month and lasting more than 1 month.
The SF-36 is scored from 0 to 100, with a higher
number representing a better HRQL (24,25). The SF-
36 includes 36 items, and has been widely used in
the medical literature to measure physical and men-
tal HRQL. Specific HRQL aspects may be ascertained
using eight separate domains, which are physical
functioning, role limitation caused by physical health
problems, bodily pain, general health, vitality, social
functioning, role limitation caused by emotional
problems, and mental health. We computed two
summary scores, the physical component summary
(PCS) and mental component summary (MCS),
using regression weights derived from principal com-
ponent factor analysis. The PCS and MCS scales
summarise the 8 HRQL aspect scores into two sum-
mary scores that give an overall assessment of the
quality of life related to physical and mental health,
respectively (24,25). Reliability and validity tests of
the SF-36 Taiwan version satisfied most conventional
psychometric criteria (26–28), and we obtained
approval to use the SF-36 Taiwan version.
Procedure
In the pilot study, a research nurse trained by the
principal investigator interviewed 30 cancer patients
at one selected hospital. Participants were inter-
viewed (20–30 min) in a private area at the outpa-
tient department. The research nurse extracted the
patients’ disease-related information (e.g. cancer
diagnosis and received treatment) from their medical
records. The research nurse also measured the
patient’s body height/weight, recorded the partici-
pant’s responses, and collected information using the
study questionnaire. Each participant received a copy
of the informed consent letter, a questionnaire, and a
gift of US$10. The main study used a data collection
procedure similar to that of the pilot study. The per-
iod of data collection for the main study was
18 months.
Data analysis
We used IBM SPSS Statistics for Windows (IBM Cor-
poration, Armonk, NY, USA) to analyse the data. A
p-value of less than .05 was regarded as statistically
significant. Descriptive statistics were calculated to
demonstrate the prevalence of LUTS and the distri-
butions of participants’ individual characteristics,
personal habits, and HRQL. We used chi-squared
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tests to compare the prevalence of LUTS for patients
with various characteristics, and adopted multivariate
logistic regression (backward elimination model) to
identify factors associated with LUTS. The variable
selection procedure, based on the process proposed
by Hosmer and Lemeshow (29), began with univari-
ate analyses of each independent variable. Any vari-
able with a univariable chi-squared test that had a p-
value of less than .25 was a candidate for the multi-
variable model. After identifying all significant pre-
dictors (p < .05) for LUTS, we examined the effects
of the first-order interactions (29). The final model
obtained estimated odds ratios and associated 95%
confidence intervals (CI) for the presence of LUTS
for each independent variable while controlling for
the other independent variables. Student t-tests were
used to compare the mean scores of the PCS, MCS,
and 8 HRQL aspects in the SF-36 for participants
with and without LUTS.
Results
All participants in this study were native Taiwanese.
Most of the cancer patients were women (n = 77,
57.5%), more than 45 years of age (n = 119, 88.8%),
and had a normal body mass index (n = 85, 63.4%)
(Table 1). Table 2 shows the distribution of partici-
pants’ personal habits. Most participants had good
bladder habits and fluid consumption habits.
Of the 134 participants, 99 (73.9%) experienced at
least one type of LUTS. The prevalence of different
LUTS ranged from 3.7% (hesitancy) to 52.2% (noct-
uria). Participants were more likely to experience
storage symptoms than voiding or post-micturition
symptoms. Table 3 shows the prevalence of LUTS
for different cancer diagnoses. The prevalence of any
LUTS in lung cancer patients was lower than the
rates in patients with other types of cancer.
We did not conduct data analyses separately based
on a participant’s treatment status because the preva-
lence of LUTS for cancer patients under active treat-
ment (n = 58, 72.5%), post-treatment less than
6 months (n = 21, 70.0%), and post-treatment more
than 6 months (n = 20, 83.3%) was not statistically
significantly different (p = .491), and the three
groups had few participants. The results of the chi-
squared tests showed that (1) participants who
received radiotherapy (n = 35, 85.4%) were more
likely to experience LUTS than those who did not
(n = 64, 68.8%) (p = .044), and (2) participants who
were diagnosed with cancer for more than
18 months (n = 49, 86.0%) were more likely to
experience LUTS than those who were diagnosed
with cancer for less than 18 months (n = 50, 64.9%)
(p = .006).
The multivariate logistic regression model in this
study identified two factors associated with LUTS.
Participants who received radiotherapy had 3.0 times
(p = .033, 95% CI = 1.0, 8.0) higher odds of experi-
encing LUTS than those who did not receive radio-
therapy. Participants diagnosed with cancer for more
than 18 months had 3.6 times (p = .005, 95%
CI = 1.5, 8.8) higher odds of experiencing LUTS
than those who were diagnosed with cancer for less
than 18 months. The final model showed no interac-
tion effect.
Table 4 presents information about the norms of
the SF-36 for Taiwanese ages 12 years and above
(28). Participants without LUTS reported higher
mean scores of HRQL (PCS, MCS, and 5 HRQL
aspects in the SF-36) than participants with LUTS.
Eight HRQL scores for all participants (with or with-
out LUTS) were all below the norms for Taiwanese,
indicating below-average HRQL. The mean scores of
HRQL were significantly different for participants
with and without LUTS on two HRQL aspects: phys-
ical functioning and role limitation caused by physi-
cal health problems (Table 4). Participants with
LUTS reported mild to moderate LUTS-related irri-
tations in their daily lives (n = 44, 44.4%) and sleep
(n = 46, 46.5%). Only 17 (17.2%) of participants
with LUTS had mentioned their LUTS to health care
providers.
Discussion
Prevalence of LUTS
This study uses 3 population-based studies on LUTS
in men and women to compare with the current
results (7–9). In these studies, the prevalence of LUTS
ranged from 61% to 64% (8,9). Storage LUTS were
more prevalent than voiding or post-micturition
LUTS (8,9), and nocturia ( 1 episode/night) was
the most common LUTS (37–76%) (7–9). A more
restrained definition of nocturia ( 2 episodes/
night) yielded a lower prevalence: the prevalence of
LUTS decreased to 47–48% (8), and the prevalence of
nocturia decreased to 10–34% (7–9). Other popula-
tion-based studies were excluded from comparison
because they used different LUTS classification meth-
ods (11,31), were conducted among a single sex
(30,31)/a specific age group (32,33), or did not report
the prevalence of individual LUTS (34,35).
This study shows that storage is the most common
group of LUTS, and nocturia is the most prevalent
symptom. These findings are consistent with the
reported prevalence patterns in previous research (7–
9). However, the prevalence of any LUTS (73.9%)
and nocturia (52.2%) was higher than the rates
reported in earlier studies (8,9). The age of partici-
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pants might explain the high prevalence in this study
because LUTS increase with age (8,36,37). Study
results show significant associations between LUTS
and anxiety/depression (10), and LUTS severity and
sleep disturbance severity (13). Chronic anxiety,
depression, and sleep disorders are the main factors
associated with LUTS (36,37). The possibility of neu-
rochemical changes in the central nervous system
(CNS) that could predispose a patient to depression
also influences the autonomic neural activity regulat-
ing the urinary tract (37). Klausner and Steers (38)
proposed that corticotrophin-releasing factor is
expressed in the areas of the CNS that control void-
ing and response to stress. This corticotrophin-releas-
ing factor also increases during anxiety, depression,
and pain. Thus, possible associations between LUTS
and these conditions cannot be excluded because
these conditions are common among cancer patients
(39–41). A high prevalence of LUTS supports the
need for appropriate pain, mental health, and sleep
disturbance assessments when LUTS are present.
Individual LUTS
The prevalence of most individual LUTS in this
study is higher than that reported in two studies
(participant age  18 years) (8,9), and similar to or
lower than the rates reported in another study (par-
ticipant age  40 years, and frequency of LUTS at
least sometimes) (7). The prevalence of weak urinary
stream is similar to that reported in the Lee et al.
study (9), and the prevalence of some individual
LUTS (e.g. urgency or incomplete emptying) is simi-
lar to the rates found in those aged  60 years (8).
These discrepancies might be the result of different
sample characteristics or data collection methods,
making a direct comparison with this study difficult.
The high prevalence of nocturia warrants special
attention. Potential factors underlying nocturia
include reduced bladder capacity, sleep disorders, 24-h
polyuria, and nocturnal polyuria (42). For example,
detrusor over-activity and bladder hypersensitivity are
Table 1 Individual characteristics (n = 134)
Variables n %
Sex
Female 77 57.5
Male 57 42.5
Age (Range: 27–92, Mean = 60.6, SD = 13.1)
≦ 45 15 11.2
46–55 30 22.4
56–65 39 29.1
> 65 50 37.3
Body mass index (Range: 15.6–38.3, Mean = 23.5,
SD = 3.8)
< 18.5 underweight 9 6.7
18.5–24.9 normal 85 63.4
≧ 25 overweight 40 29.9
Marital status
Married 107 79.9
Single (separated, divorced, or widowed) 19 14.2
Single, never married 8 5.9
Primary cancer site
Breast 39 29.1
Lung 30 22.4
Colorectal 17 12.7
Female genital system
[cervical (9), and ovarian (2)]
11 8.2
Other [oesophagus (8),
lymphoma (6), stomach (6),
bladder (6), thymus gland (4),
thyroid (3), pancreas (3), liver (1)]
37 27.6
Cancer stage
I 16 11.9
II 51 38.1
III 42 31.3
IV 25 18.7
Time since diagnosis of cancer
6 months–18 months 77 57.5
18 months–3 years 46 34.3
3 years–5 years 11 8.2
Treatment(s) received
Chemotherapy or target therapy + surgery 51 38.1
Radiotherapy + chemotherapy
or target therapy + surgery
29 21.6
Chemotherapy or target therapy 24 17.9
Surgery 16 11.9
Radiotherapy + chemotherapy or
target therapy
12 9.0
Endocrine therapy + surgery 2 1.5
Treatment status
Active treatment 80 59.7
Post-treatment ≦ 6 months 30 22.4
Post-treatment > 6 months 24 17.9
Other chronic disease
Yes 22 16.4
Diabetes (18) (13.4)
Neurologic disorders (3) (2.2)
Diabetes and neurologic disorders (1) (0.8)
No 112 83.6
Table 1 Continued
Variables n %
Chronic constipation
Yes 36 26.9
No 98 73.1
Chronic cough
Yes 36 26.9
No 98 73.1
Abdominal or spinal surgery
Yes 78 58.2
No 56 41.8
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related to bladder storage, and excessive evening intake
of fluid/caffeine and oestrogen deficiency are related
to nocturnal polyuria (42). Further studies should
investigate the possible causes of nocturia in cancer
patients by obtaining information from a voiding
diary, urodynamics analysis, or a sleep laboratory.
Nocturia has a wide range of negative consequences,
including sleep disturbance, mood disturbance, poor
overall health, reduced HRQL, and increased falls and
fractures (43). Health care providers should be aware
that cancer patients may be affected by nocturia, and
offer appropriate management or treatments.
LUTS in various types of cancer
A recent systematic review of 16 studies suggested
that urinary symptoms are prevalent among breast
cancer patients (44). The results of the current study
support this conclusion. Breast cancer occurs primar-
ily in women around menopause, and ovarian sup-
pression or failure after chemotherapy is related to
early menopause (44). Hormone-related symptoms,
such as vasomotor and urogenital symptoms, are
prevalent after chemotherapy or endocrine therapy
in breast cancer patients (45,46). When women are
diagnosed with breast cancer, they typically cease
their hormone replacement therapy, which may
intensify the menopausal symptoms (45). Common
side effects of radiotherapy (e.g. fatigue, pain, depres-
sion, and sleeping difficulties) in breast cancer
patients (46) might also be related to LUTS (36–38).
Therefore, future research should investigate the pos-
sible associations among menopausal status, treat-
ments received, and LUTS in breast cancer patients.
Early studies investigating the symptoms or symp-
tom clusters of lung cancer patients seldom
addressed LUTS. Gift et al. (5) reported that nocturi-
a was a prevalent symptom (n = 149, 68%) among
lung cancer patients. Participants’ age (65–89 years
of age) is a possible explanation of the high preva-
lence rate in the Gift et al. study (5) because nocturi-
a is common among older persons (43). Information
about the association between lung cancer treatments
and LUTS is limited. Common symptoms appearing
among cancer patients (39,41) might be a reasonable
explanation (36–38) for the high prevalence (60.0%)
in this study.
Pelvic radiotherapy has negative effects on the
lower urinary tract, and severe urinary adverse effects
are common after prostate, bladder, and cervical
radiotherapy (47). The incidence of lower urinary
tract dysfunction after abdominoperineal resection,
low anterior resection, and radical hysterectomy is
well recognised (48). Aggressive pelvic surgery aimed
at reducing the risk of cancer recurrence can also
increase genitourinary morbidity. Pelvic surgery may
also damage the lower urinary tract and main uro-
genital nerves (e.g. somatic pudendal nerves). Post-
operative scarring, tissue hypoxia resulting from
impaired blood flow to the pelvic organs, and conse-
quent bladder wall fibrosis may have negative effect
on the lower urinary tract. The partial excision of
the vaginal wall, which is sometimes necessary for
women with genital system cancer, may impair the
anatomy and function of the urinary tract (48).
Chemotherapy, radiotherapy, and surgery are com-
mon treatments for patients with colorectal or female
genital system cancer. Previous research has shown
that long-term UI (38%) and incomplete emptying
(31%) are prevalent among postoperative rectal can-
cer patients (n = 785) (49), and the prevalence of
lower urinary tract dysfunction among gynaecologic
Table 2 Personal habits (n = 134)
Variables n %
Smoking habit
Yes 6 4.5
No 128 95.5
Bladder habit
Good 129 96.3
Poor 5 3.7
Delay urinating
Never 83 61.9
Sometimes (1 day a week or less) 35 26.1
Usually (2 or 3 days a week) 13 9.7
Always (every day or nearly every day) 3 2.2
Reduce fluid consumption to prolong urination interval
or to avoid urination
Never 101 75.4
Sometimes (1 day a week or less) 24 17.9
Usually (2 or 3 days a week) 5 3.7
Always (every day or nearly every day) 4 3.0
Fluid consumption habit
Good 119 88.8
Poor 15 11.2
Did not drink fluid until thirsty
Never 65 48.5
Sometimes (1 day a week or less) 21 15.7
Usually (2 or 3 days a week) 19 14.2
Always (every day or nearly every day) 29 21.6
Ignored fluid consumption because of discomfort
Never 109 81.3
Sometimes (1 day a week or less) 16 11.9
Usually (2 or 3 days a week) 9 6.7
Always (every day or nearly every day) 0 0
Fluid intake (ml/day)
< 1500 ml/day 77 57.5
1500–3000 ml/day 51 38.1
> 3000 ml/day 6 4.4
Caffeine consumption
Yes 44 32.8
No 90 67.2
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cancer survivors is high (65%) (n = 108) (50). Sur-
gery or radiotherapy-related nerve injury, pelvic floor
damage, urinary tract dysfunction, and pelvis anat-
omy change, and chemotherapy-related oestrogen
deficiency in female patients could be possible expla-
nations (47,48,50) for the high prevalence of LUTS
among these groups. The sample in this study
included a small number of participants with colorec-
tal or female genital system cancer. To examine the
possible effects of varied treatments on the lower uri-
nary tract, further research should analyse an ade-
quate sample size for these specific groups.
People with cancer diagnoses seldom discuss LUTS
with health care providers because LUTS are not of
major concern during treatment. Health care provid-
ers, and particularly oncology health care providers,
should receive adequate training to screen for LUTS
in this population to offer management/treatment
recommendations based on available guidelines
(51,52). Previous research has reported the beneficial
effects of behavioural interventions (e.g. healthy
bladder habits or lifestyle modifications) for preven-
tion and treatment of LUTS (53–56). Helpful strate-
gies, such as pelvic floor muscle training, bladder
training, establishment of normal voiding intervals,
elimination of bladder irritants from the diet, and
management of fluid intake and bowel regularity,
could be incorporated into patients’ daily lives (53–
56). However, instead of increasing the burden of
cancer patients, encouraging the adoption of these
self-management practices to relieve LUTS when liv-
ing with cancer may improve patients’ self-efficacy,
overall wellness, and HRQL.
Associated factors
The factors of age, body mass index, obstetric/gynae-
cological factors, psychological factors (e.g. anxiety or
depression), and certain lifestyle factors (e.g. sleep dis-
orders or bladder habit) may be associated with LUTS
(20,36,37). Applying the multivariate logistic regres-
sion model in this study to the information collected
from 77 female participants failed to identify obstet-
ric/gynaecological factors as significant factors associ-
ated with LUTS. The inability of this study to identify
these common associated factors might result from
the uneven distributions of variables (e.g. age, body
mass index, and personal habits) and a small sample
size. Future research investigating factors associated
with LUTS could involve healthy non-cancer control
groups. The section entitled ‘LUTS in various types of
cancer’ presents a discussion on the association
between radiotherapy and LUTS. Thus, the following
discussion focuses on the association between the
time since the diagnosis of cancer and LUTS.
Few studies have investigated late adverse effects
of cancer treatments, particularly regarding urinary
adverse effects (47,49,57,58). Ganz et al. reported
that UI symptoms increased among breast cancer
survivors (n = 763) with initial and follow-up sur-
veys at an average of 3.4 years and 6.3 years after
diagnosis (57), respectively. Peeter et al. reported
that approximately 40% of rectal cancer patients
(n = 597) reported UI, and 57% of them wore pads
because of UI (follow-up range: 2.6–7.6 years),
regardless of receiving radiotherapy plus surgery or
surgery alone (58). Lang et al. followed post-treat-
ment urinary dysfunction for 5 years among rectal
Table 3 Prevalence rates of LUTS (n = 134)
LUTS
All (n = 134)
Breast cancer
(n = 39)
Lung cancer
(n = 30)
Colorectal cancer
(n = 17)
Female genital
system cancer
(n = 11)
Yes, n (%) Yes, n (%) Yes, n (%) Yes, n (%) Yes, n (%)
Any LUTS 99 (73.9) 31 (79.5) 18 (60.0) 12 (70.6) 9 (81.8)
Storage symptom 92 (68.7) 28 (71.8) 16 (53.3) 11 (64.7) 9 (81.8)
Nocturia ( 2 episodes/night) 70 (52.2) 17 (43.6) 15 (50.0) 10 (58.8) 7 (63.6)
Urinary incontinence 34 (25.4) 11 (28.2) 4 (13.3) 5 (29.4) 2 (18.2)
Increased daytime urinary frequency 33 (24.6) 9 (23.1) 3 (10.0) 3 (17.6) 0 (0.0)
Urinary urgency 24 (17.9) 10 (25.6) 2 (6.7) 2 (11.8) 2 (18.2)
Voiding symptom 34 (25.4) 11 (28.2) 7 (23.3) 4 (23.5) 1 (9.1)
Intermittent stream 26 (19.4) 7 (17.9) 7 (23.3) 3 (17.6) 1 (9.1)
Weak urinary stream 21 (15.7) 7 (17.9) 3 (10.0) 3 (17.6) 1 (9.1)
Hesitancy 5 (3.7) 2 (5.1) 0 (0.0) 1 (5.9) 0 (0.0)
Post-micturition symptom 27 (20.1) 11 (28.2) 2 (6.7) 2 (11.8) 3 (27.3)
Incomplete emptying 27 (20.1) 11 (28.2) 2 (6.7) 2 (11.8) 3 (27.3)
LUTS, lower urinary tract symptoms.
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cancer patients (n = 785) and reported that UI
increased over time (49). Elliott and Malaeb reviewed
the long-term adverse effects of pelvic radiotherapy
and concluded that urinary adverse effects continue
to accrue over time (47).
The results of the current study warrant special
concern for late urinary adverse effects after cancer
treatment. Only 18 (13.4%) of participants in this
study did not receive chemotherapy or radiotherapy.
However, a cross-sectional study cannot examine the
association between past adjuvant treatment and
LUTS, and this topic requires further exploration.
Further research conducted in larger, more homoge-
neous samples and with a longitudinal design might
be an appropriate approach.
HRQL, bothers and help-seeking behaviours
These results are consistent with those reported in pre-
vious research (10,11,14). The HRQL scores for partici-
pants with LUTS were lower than those for participants
without LUTS (10,11), and only a few participants with
LUTS seek professional help (14,15). However, 44–47%
of participants with LUTS in this study reported mild
to moderate disturbances in daily life and sleep. The
differences between cancer patients with and without
LUTS were non-significant in 6 HRQL aspects: bodily
pain, general health, vitality, social functioning, role
limitation caused by emotional problems, and mental
health. These non-significant findings might result from
the overall poor state of health, poor mental health and
wellness among cancer patients (39–41). Because cancer
patients may be reluctant to disclose LUTS, and oncol-
ogy health care providers seldom focus on LUTS, the
high prevalence of LUTS and poor help-seeking behav-
iours shown in this study highlight the need for screen-
ing/managing LUTS.
This study has several limitations. First, a cross-sec-
tional design can only suggest an association, and
Table 4 Comparison of the HRQL for Participants with and without LUTS (n = 134)
HRQL (Norms of Taiwanese ages 12 years and above)* Participants Mean  SD t p
Physical component summary (PCS) All (n = 134) 44.8  11.4 1.74 0.087
With LUTS (n = 99) 43.8  11.6
Without LUTS (n = 35) 47.5  10.8
Physical functioning (92.2  12.2) All 71.2  25.3 2.78 0.007‡
With LUTS 68.1  26.4
Without LUTS 79.9  19.5
Role limitation caused by physical health problems (83.7  33.3) All 42.7  44.9 -2.07 0.043†
With LUTS 37.9  43.6
Without LUTS 56.4  46.3
Bodily pain (84.8  19.4) All 79.6  22.1 0.14 0.890
With LUTS 79.4  22.5
Without LUTS 80.0  21.1
General health (69.3  21.3) All 62.4  23.6 0.45 0.653
With LUTS 63.0  22.5
Without LUTS 60.7  26.7
Mental component summary (MCS) All 47.1  13.7 0.73 0.470
With LUTS 46.6  13.8
Without LUTS 48.5  13.5
Vitality (68.3  18.7) All 57.7  22.9 0.11 0.916
With LUTS 57.3  22.7
Without LUTS 57.8  23.8
Social functioning (86.8  17.1) All 72.8  24.5 1.49 0.142
With LUTS 71.1  25.6
Without LUTS 77.5  20.5
Role limitation caused by emotional problems (79.4  36.1) All 63.9  45.9 1.50 0.139
With LUTS 60.6  47.0
Without LUTS 73.3  41.9
Mental health (73.0  16.6) All 66.7  18.8 0.48 0.632
With LUTS 67.2  17.1
Without LUTS 65.1  23.0
*Source: Tseng et al., 2003; Values given are Mean  SD. †p < 0.05; ‡p < 0.01. HRQL, health related quality of life; LUTS, lower
urinary tract symptoms.
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cannot demonstrate a causal relationship. Second, the
relatively small sample size and sample exclusion (e.g.
cognitive impairment) in this study might reduce the
generalizability of these results. Third, heterogeneity
of the sample regarding cancer types, time since diag-
nosis, and treatment status might affect the LUTS
estimates. Fourth, recall bias cannot be excluded.
Some studies have investigated LUTS based on partic-
ipants’ experience during the past 4 weeks/1 month
(7,8,34,35), and studies investigating UI in the previ-
ous year are also available (59–62). To facilitate com-
parisons between studies, future studies should collect
information during the past 4 weeks/1 month. Fifth,
the psychometric assessment for the study question-
naire must be refined. Future studies could use objec-
tive examinations (e.g. voiding diary or urodynamic
assessments) to validate self-reported LUTS.
Conclusion
This preliminary study contributes to knowledge
about LUTS among cancer patients in Taiwan and
increases awareness of this health concern. These
results show that LUTS are common among this spe-
cific group, suggesting that further research should
be conducted with larger, more homogeneous sam-
ples. Results show that radiotherapy and the time
since the diagnosis of cancer might be linked to
LUTS. Further research based on cancer patients’
treatment status might be appropriate because LUTS
prevalence, severity, and causes can differ at various
treatment states. Given the improved survivorship of
people diagnosed with different cancers, health care
providers should screen for LUTS, deliver adequate
management/treatment of LUTS, provide individua-
lised intervention of LUTS, and make appropriate
referrals to optimise cancer patients’ HRQL.
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